Regeneron Pharmaceuticals Inc (REGN) - Financial and Strategic SWOT Analysis Review

Date: March 1, 2017
Pages: 62
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: R8CF600A833EN
Leaflet:

Download PDF Leaflet

Regeneron Pharmaceuticals Inc (REGN) - Financial and Strategic SWOT Analysis Review
Regeneron Pharmaceuticals Inc (REGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Regeneron Pharmaceuticals Inc (Regeneron) is a biopharmaceutical company which discovers, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The company provides products for treating eye diseases, high low-density lipoprotein (LDL) cholesterol, a rare inflammatory condition, rheumatoid arthritis and metastatic colorectal cancer. It develops products based on its VelociSuite technology platforms, which include VelociGene, VelocImmune, VelociMouse, VelociMab and other related technologies. Regeneron is also developing various product candidates in clinical development for treating asthma, pain, cancer, atopic dermatitis and infectious diseases. It has subsidiaries in Belgium, Spain, the Netherlands, the US and the UK. Regeneron is headquartered in Tarrytown, NewYork, the US.

Regeneron Pharmaceuticals Inc Key Recent Developments

Feb 09, 2017: Regeneron Reports Fourth Quarter And Full Year 2016 Financial And Operating Results
Jan 31, 2017: Tony Coles, M.D., Elected To Regeneron Board Of Directors
Jan 04, 2017: Regeneron Hires Jay Markowitz, M.D., As Senior Vice President Of Portfolio Management
Dec 22, 2016: Regeneron Genetics Center and Geisinger Study Finds Life-Threatening Genetic Disorder is Substantially Underdiagnosed
Dec 22, 2016: Science Publication Highlights the Precision Medicine Approach of the Regeneron Genetics Center and Geisinger Health System

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

Regeneron Pharmaceuticals Inc - Key Facts
Regeneron Pharmaceuticals Inc - Key Employees
Regeneron Pharmaceuticals Inc - Key Employee Biographies
Regeneron Pharmaceuticals Inc - Major Products and Services
Regeneron Pharmaceuticals Inc - Pharmaceutical Pipeline Products Data
Regeneron Pharmaceuticals Inc, Pipeline Products by Therapy Area
Regeneron Pharmaceuticals Inc, Pipeline Products by Development Phase
Regeneron Pharmaceuticals Inc - History
Regeneron Pharmaceuticals Inc - Company Statement
Regeneron Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Regeneron Pharmaceuticals Inc - Business Description
Regeneron Pharmaceuticals Inc - Corporate Strategy
Regeneron Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Regeneron Pharmaceuticals Inc - Strengths
Regeneron Pharmaceuticals Inc - Weaknesses
Regeneron Pharmaceuticals Inc - Opportunities
Regeneron Pharmaceuticals Inc - Threats
Regeneron Pharmaceuticals Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Regeneron Pharmaceuticals Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Feb 09, 2017: Regeneron Reports Fourth Quarter And Full Year 2016 Financial And Operating Results
Jan 31, 2017: Tony Coles, M.D., Elected To Regeneron Board Of Directors
Jan 04, 2017: Regeneron Hires Jay Markowitz, M.D., As Senior Vice President Of Portfolio Management
Dec 22, 2016: Regeneron Genetics Center and Geisinger Study Finds Life-Threatening Genetic Disorder is Substantially Underdiagnosed
Dec 22, 2016: Science Publication Highlights the Precision Medicine Approach of the Regeneron Genetics Center and Geisinger Health System
Nov 09, 2016: Mount Sinai Health System Launches Collaboration With the Regeneron Genetics Center
Nov 04, 2016: Regeneron Reports Third Quarter 2016 Financial and Operating Results
Sep 12, 2016: Regeneron Announces Election of Bonnie Bassler, Ph.D., and Huda Zoghbi, M.D., to Board of Directors
Aug 22, 2016: Regeneron Announces Agreement with BARDA for the Manufacturing and Testing of New Antibodies Against MERS Virus
Aug 04, 2016: Regeneron Reports Second Quarter 2016 Financial and Operating Results

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Regeneron Pharmaceuticals Inc, Key Facts
Regeneron Pharmaceuticals Inc, Key Employees
Regeneron Pharmaceuticals Inc, Key Employee Biographies
Regeneron Pharmaceuticals Inc, Major Products and Services
Regeneron Pharmaceuticals Inc, Number of Pipeline Products by Therapy Area
Regeneron Pharmaceuticals Inc, Number of Pipeline Products by Development Stage
Regeneron Pharmaceuticals Inc, History
Regeneron Pharmaceuticals Inc, Other Locations
Regeneron Pharmaceuticals Inc, Subsidiaries
Regeneron Pharmaceuticals Inc, Key Competitors
Regeneron Pharmaceuticals Inc, Ratios based on current share price
Regeneron Pharmaceuticals Inc, Annual Ratios
Regeneron Pharmaceuticals Inc (Cont.1), Annual Ratios
Regeneron Pharmaceuticals Inc, Interim Ratios
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Regeneron Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Regeneron Pharmaceuticals Inc, Pipeline Products by Therapy Area
Regeneron Pharmaceuticals Inc, Pipeline Products by Development Phase
Regeneron Pharmaceuticals Inc, Performance Chart (2012 - 2016)
Regeneron Pharmaceuticals Inc, Ratio Charts
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

COMPANIES MENTIONED

Sanofi
Pfizer Inc
Onyx Pharmaceuticals Inc
Novartis AG
Merck & Co Inc
Genentech Inc
Eli Lilly and Company
Bayer AG
Amgen Inc
Allergan Inc
Abbott Laboratories
Skip to top


Ask Your Question

Regeneron Pharmaceuticals Inc (REGN) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: